Literature DB >> 23257943

Solitaire FR device for treatment of dural sinus thrombosis.

Bryan Anthony Pukenas1, Monisha Kumar, Michael Stiefel, Michelle Smith, Robert Hurst.   

Abstract

Dural venous sinus thrombosis is a rare and potentially devastating disease. Several predisposing factors exist, including oral contraceptive therapy and colitis. First-line therapy consists of systemic anticoagulation. If first-line therapies fail, more aggressive endovascular therapies may be performed. We report our initial experience with the Solitaire FR device for treatment of refractory symptomatic dural venous sinus thrombosis.

Entities:  

Mesh：

Year:  2012        PMID： 23257943      PMCID： PMC4545054          DOI： 10.1136/bcr-2012-010543

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  23 in total

1.  In vitro effectiveness study of three hydrodynamic thrombectomy devices.

Authors:  S Müller-Hülsbeck; C Bangard; H Schwarzenberg; C C Glüer; M Heller
Journal:  Radiology       Date:  1999-05       Impact factor: 11.105

Review 2.  Cerebral venous thrombosis: an update.

Authors:  Marie-Germaine Bousser; José M Ferro
Journal:  Lancet Neurol       Date:  2007-02       Impact factor: 44.182

3.  Extensive dural sinus thrombosis: successful recanalization with thrombolysis and a novel thrombectomy device.

Authors:  Kristine A Blackham
Journal:  J Neurosurg       Date:  2010-03-05       Impact factor: 5.115

4.  EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients.

Authors:  K Einhäupl; J Stam; M-G Bousser; S F T M De Bruijn; J M Ferro; I Martinelli; F Masuhr
Journal:  Eur J Neurol       Date:  2010-10       Impact factor: 6.089

5.  Endovascular treatment of acute intracerebral artery occlusions with the solitaire stent: single-centre experience with 108 recanalization procedures.

Authors:  F Dorn; S Stehle; H Lockau; C Zimmer; T Liebig
Journal:  Cerebrovasc Dis       Date:  2012-06-30       Impact factor: 2.762

Review 6.  Thrombolytics for cerebral sinus thrombosis: a systematic review.

Authors:  Patricia Canhão; Filipa Falcão; José M Ferro
Journal:  Cerebrovasc Dis       Date:  2003       Impact factor: 2.762

7.  Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT).

Authors:  José M Ferro; Patrícia Canhão; Jan Stam; Marie-Germaine Bousser; Fernando Barinagarrementeria
Journal:  Stroke       Date:  2004-02-19       Impact factor: 7.914

8.  Urokinase treatment of sagittal sinus thrombosis with venous hemorrhagic infarction.

Authors:  S E Kasner; J H Gurian; J C Grotta
Journal:  J Stroke Cerebrovasc Dis       Date:  1998 Nov-Dec       Impact factor: 2.136

9.  Coil embolization of anterior circulation aneurysms supported by the Solitaire AB Neurovascular Remodeling Device.

Authors:  Joachim Klisch; Christin Clajus; Vojtech Sychra; Cornelia Eger; Christoph Strasilla; Steffen Rosahl; Rüdiger Gerlach; Ingrid Bär; Heinrich Hoch; Uta Herbon; Ljubisa Borota; Per Jonasson; Thomas Liebig
Journal:  Neuroradiology       Date:  2009-07-31       Impact factor: 2.804

10.  Rheolytic thrombectomy for dural venous sinus thrombosis.

Authors:  Kalgi Modi; Vijay Misra; Pratap Reddy
Journal:  J Neuroimaging       Date:  2008-10-21       Impact factor: 2.486
View more
  3 in total

Review 1.  Endovascular treatments for cerebral venous sinus thrombosis.

Authors:  Zhongming Qiu; Hongfei Sang; Qiliang Dai; Gelin Xu
Journal:  J Thromb Thrombolysis       Date:  2015-10       Impact factor: 2.300

2.  Superior gluteal artery injury risk from third sacral segment transsacral screw insertion.

Authors:  Jonathan G Eastman; Quintin A Kuse; Milton L Chip Routt; Trevor J Shelton; Mark R Adams
Journal:  Eur J Orthop Surg Traumatol       Date:  2021-07-05

Review 3.  New Developments in the Pathophysiology, Workup, and Diagnosis of Dural Venous Sinus Thrombosis (DVST) and a Systematic Review of Endovascular Treatments.

Authors:  Sanjay Konakondla; Clemens M Schirmer; Fengwu Li; Xiaogun Geng; Yuchuan Ding
Journal:  Aging Dis       Date:  2017-04-01       Impact factor: 6.745
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.